Talk to the Institute
Published mark

Black Diamond Therapeutics, Inc.

NASDAQ: BDTX. Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:ec96f1da-a1c7-40b7-9eee-0f8ac32f0b45
SEC CIK
0001701541
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 17, 2026
Newest evidence
Apr 18, 2025
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Not published
Chair
Not published
Independent
6 / 77 directors published
Published claims
152 distinct sources
Evidence records
30 pinned
Source conflicts
0None open

Built from 2 distinct sources and 3 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

DIRECTOR APPOINTED

Prakash Raman, Ph.D. seat on Black Diamond Therapeutics, Inc., effective 2024-01-01.

EffectiveEffective Jan 1, 2024E2

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Board of directors

Evidence

7 directors published. 6 of 7 with a published determination are independent.

DirectorStatusSinceCommitteesClaim
Ali Behbahani, M.D.Independent2018None publishedSource reportedE2
Garry E. Menzel, Ph.D.Independent2017None publishedSource reportedE2
Kapil Dhingra, M.B.B.S.Independent2021None publishedSource reportedE2
Mark A. Velleca, M.D., Ph.D.Not independent2021None publishedSource reportedE2
Prakash Raman, Ph.D.Independent2024None publishedSource reportedE2
Samarth Kulkarni, Ph.D.Independent2019None publishedSource reportedE2
Shannon CampbellIndependent2022CompensationSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
CompensationNot publishedShannon CampbellNot described in the published record
Committee RecordCompensation: Chair not stated; Members Shannon Campbell
Source reportedE3
company:ec96f1da-a1c7-40b7-9eee-0f8ac32f0b45:committee_record:14
Committee AppointmentShannon Campbell: member, Compensation
Source reportedE3
company:ec96f1da-a1c7-40b7-9eee-0f8ac32f0b45:committee_appointment:15

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingBDTX (NASDAQ)
Source reportedE1
company:ec96f1da-a1c7-40b7-9eee-0f8ac32f0b45:security_listing:16
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 17, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameBlack Diamond Therapeutics, Inc.
Source reportedE1
company:ec96f1da-a1c7-40b7-9eee-0f8ac32f0b45:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:ec96f1da-a1c7-40b7-9eee-0f8ac32f0b45:entity_status:3
Published FactHealthcare
Source reportedE1
company:ec96f1da-a1c7-40b7-9eee-0f8ac32f0b45:published_fact:5
Published FactBiotechnology
Source reportedE1
company:ec96f1da-a1c7-40b7-9eee-0f8ac32f0b45:published_fact:6

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • LeadershipNot reviewed. Executive leadership carries operating authority.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
3 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 17, 2026. Cited by 6 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    Black Diamond Therapeutics, Inc. DEF 14A 2025-04-18
    sec proxy. Published Apr 18, 2025. Retrieved Apr 28, 2026. Cited by 7 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    Compensation
    board_seats. board seats. Cited by 2 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 17, 2026
  • Prakash Raman, Ph.D. seat on Black Diamond Therapeutics, Inc., effective 2024-01-01.
  • Shannon Campbell seat on Black Diamond Therapeutics, Inc., effective 2022-01-01.
  • Shannon Campbell member of Compensation, effective 2022-01-01.
  • Kapil Dhingra, M.B.B.S. seat on Black Diamond Therapeutics, Inc., effective 2021-01-01.
  • Mark A. Velleca, M.D., Ph.D. seat on Black Diamond Therapeutics, Inc., effective 2021-01-01.
  • Samarth Kulkarni, Ph.D. seat on Black Diamond Therapeutics, Inc., effective 2019-01-01.
  • Ali Behbahani, M.D. seat on Black Diamond Therapeutics, Inc., effective 2018-01-01.
  • Garry E. Menzel, Ph.D. seat on Black Diamond Therapeutics, Inc., effective 2017-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:ec96f1da-a1c7-40b7-9eee-0f8ac32f0b45, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/black-diamond-therapeutics-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership0
  4. Board7
  5. Committees1
  6. Control and voting0
  7. Authority to act3
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims5
  15. Coverage gaps18
  16. Linked people7
  17. Subject and corrections6
  18. Evidence3
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:ec96f1da-a1c7-40b7-9eee-0f8ac32f0b45
  • Cite this recordBlack Diamond Therapeutics, Inc.
  • Copy canonical URLregistry.alpha.ac/companies/black-diamond-therapeutics-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    Black Diamond Therapeutics, Inc.Company
  • Ali Behbahani, M.D.Person
  • Garry E. Menzel, Ph.D.Person
  • Kapil Dhingra, M.B.B.S.Person
  • Mark A. Velleca, M.D., Ph.D.Person
  • Prakash Raman, Ph.D.Person
  • Samarth Kulkarni, Ph.D.Person
  • Shannon CampbellPerson
  • Sections
    OverviewBlack Diamond Therapeutics, Inc.
  • MonitoringBlack Diamond Therapeutics, Inc.
  • LeadershipBlack Diamond Therapeutics, Inc.
  • BoardBlack Diamond Therapeutics, Inc.
  • CommitteesBlack Diamond Therapeutics, Inc.
  • Control and votingBlack Diamond Therapeutics, Inc.
  • Authority to actBlack Diamond Therapeutics, Inc.
  • FinancialsBlack Diamond Therapeutics, Inc.
  • GovernanceBlack Diamond Therapeutics, Inc.
  • RiskBlack Diamond Therapeutics, Inc.
  • AI oversightBlack Diamond Therapeutics, Inc.
  • LegalBlack Diamond Therapeutics, Inc.
  • CompensationBlack Diamond Therapeutics, Inc.
  • Other published claimsBlack Diamond Therapeutics, Inc.
  • Coverage gapsBlack Diamond Therapeutics, Inc.
  • Linked peopleBlack Diamond Therapeutics, Inc.
  • Subject and correctionsBlack Diamond Therapeutics, Inc.
  • EvidenceBlack Diamond Therapeutics, Inc.
  • Version historyBlack Diamond Therapeutics, Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.